Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2003 1
2004 1
2005 1
2006 9
2007 5
2008 5
2009 8
2010 7
2011 4
2012 8
2013 1
2014 5
2015 11
2016 6
2017 6
2018 5
2019 6
2020 8
2021 6
2022 4
2023 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Results by year

Filters applied: . Clear all
Page 1
A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors.
Abuzakhm SM, Sukrithan V, Fruth B, Qin R, Strosberg J, Hobday TJ, Semrad T, Reidy-Lagunes D, Kindler HL, Kim GP, Knox JJ, Kaubisch A, Villalona-Calero M, Chen H, Erlichman C, Shah MH. Abuzakhm SM, et al. Among authors: shah mh. Endocr Relat Cancer. 2023 Sep 13;30(11):e220301. doi: 10.1530/ERC-22-0301. Print 2023 Nov 1. Endocr Relat Cancer. 2023. PMID: 37702588 Free PMC article. Clinical Trial.
Kinase inhibitors in thyroid cancers.
Sukrithan V, Jain P, Shah MH, Konda B. Sukrithan V, et al. Among authors: shah mh. Endocr Oncol. 2023 Jan 13;3(1):e220062. doi: 10.1530/EO-22-0062. eCollection 2023 Jan 1. Endocr Oncol. 2023. PMID: 37434642 Free PMC article. Review.
From bench to clinic: Emerging therapies for corneal scarring.
Yang GN, Roberts PK, Gardner-Russell J, Shah MH, Couper TA, Zhu Z, Pollock GA, Dusting GJ, Daniell M. Yang GN, et al. Among authors: shah mh. Pharmacol Ther. 2023 Feb;242:108349. doi: 10.1016/j.pharmthera.2023.108349. Epub 2023 Jan 20. Pharmacol Ther. 2023. PMID: 36682466 Review.
Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial.
Sherman EJ, Harris J, Bible KC, Xia P, Ghossein RA, Chung CH, Riaz N, Gunn GB, Foote RL, Yom SS, Wong SJ, Koyfman SA, Dzeda MF, Clump DA, Khan SA, Shah MH, Redmond K, Torres-Saavedra PA, Le QT, Lee NY. Sherman EJ, et al. Among authors: shah mh. Lancet Oncol. 2023 Feb;24(2):175-186. doi: 10.1016/S1470-2045(22)00763-X. Epub 2023 Jan 18. Lancet Oncol. 2023. PMID: 36681089 Free PMC article. Clinical Trial.
TAK1 blockade as a therapy for retinal neovascularization.
Wang JH, Lin FL, Chen J, Zhu L, Chuang YF, Tu L, Ma C, Ling D, Hewitt AW, Tseng CL, Shah MH, Bui BV, van Wijngaarden P, Dusting GJ, Wang PY, Liu GS. Wang JH, et al. Among authors: shah mh. Pharmacol Res. 2023 Jan;187:106617. doi: 10.1016/j.phrs.2022.106617. Epub 2022 Dec 16. Pharmacol Res. 2023. PMID: 36535572 Free article.
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).
Kunz PL, Graham NT, Catalano PJ, Nimeiri HS, Fisher GA, Longacre TA, Suarez CJ, Martin BA, Yao JC, Kulke MH, Hendifar AE, Shanks JC, Shah MH, Zalupski MM, Schmulbach EL, Reidy-Lagunes DL, Strosberg JR, O'Dwyer PJ, Benson AB 3rd. Kunz PL, et al. Among authors: shah mh. J Clin Oncol. 2023 Mar 1;41(7):1359-1369. doi: 10.1200/JCO.22.01013. Epub 2022 Oct 19. J Clin Oncol. 2023. PMID: 36260828 Free PMC article. Clinical Trial.
A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms.
Owen DH, Benner B, Wei L, Sukrithan V, Goyal A, Zhou Y, Pilcher C, Suffren SA, Christenson G, Curtis N, Jukich M, Schwarz E, Savardekar H, Norman R, Ferguson S, Kleiber B, Wesolowski R, Carson WE, Otterson GA, Verschraegen CF, Shah MH, Konda B. Owen DH, et al. Among authors: shah mh. Clin Cancer Res. 2023 Feb 16;29(4):731-741. doi: 10.1158/1078-0432.CCR-22-1552. Clin Cancer Res. 2023. PMID: 36255391 Free PMC article.
Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial.
Busaidy NL, Konda B, Wei L, Wirth LJ, Devine C, Daniels GA, DeSouza JA, Poi M, Seligson ND, Cabanillas ME, Sipos JA, Ringel MD, Eisfeld AK, Timmers C, Shah MH. Busaidy NL, et al. Among authors: shah mh. Thyroid. 2022 Oct;32(10):1184-1192. doi: 10.1089/thy.2022.0115. Epub 2022 Jul 5. Thyroid. 2022. PMID: 35658604 Free PMC article. Clinical Trial.
RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient.
Bagheri-Yarmand R, Busaidy NL, McBeath E, Danysh BP, Evans KW, Moss TJ, Akcakanat A, Ng PKS, Knippler CM, Golden JA, Williams MD, Multani AS, Cabanillas ME, Shaw KR, Meric-Bernstam F, Shah MH, Ringel MD, Hofmann MC. Bagheri-Yarmand R, et al. Among authors: shah mh. Cancers (Basel). 2021 Sep 30;13(19):4950. doi: 10.3390/cancers13194950. Cancers (Basel). 2021. PMID: 34638434 Free PMC article.
103 results